The global HIV diagnostics market was valued at USD 3.13 Billion in 2023. It s further predicted to be growing at a CAGR of 9.5% and a value of USD 4.93 Billion by 2028.
The human immunodeficiency virus (HIV) is a retrovirus that causes AIDS. HIV affects immune cells and further weakens the immune system bringing a loss of capacity to fight against the organisms that cause diseases.
Y-O-Y growth in the population diagnosed with HIV and the rise in demand for technologically advanced devices for diagnosing HIV with high accuracy are majorly promoting the global HIV diagnostics market growth.
Other significant factors such as the growing adoption rate of home kits for diagnosis and testing of HIV, growing investments from private and government organizations for developing effective diagnostic techniques for treating HIV patients, and the emergence of simple, rapid assays with visual testing better handling are further accelerating the growth rate of the global HIV diagnostics market.
According to WHO, people diagnosed with HIV reach millions, out of which a few million die yearly.
AIDS is the advanced stage of HIV that affects the immune system. People whose CD4 cells are lower than 200/mm are diagnosed as AIDS patients. This HIV test uses blood, serum, o urine samples, where blood samples give accurate diagnosis results. However, governments worldwide have conducted campaigns and educational seminars in colleges, corporate places, and other public places to bring awareness to people. Recently Kenya Medical Research Institute introduced its new Cobas Plasma Separation Card to collect and test samples quickly.
The inappropriate functioning of regulatory bodies with stringent rules is one of the significant restraints to market growth. Additionally, High costs associated with nucleic acid testing (NAT) and advanced diagnostics of HIV and the lack of a proper regulatory framework for NAT in developing countries are further expected to hamper the growth rate of the global HIV diagnostics market.
Impact of COVID-19 on the global HIV diagnostics market:
The emergence of the global pandemic COVID-19 has negatively impacted the HIV diagnostics market. The HIV Diagnostic market experience ed a decline in market growth during the initial period of 2020. The nationwide lockdown is imposed to disrupt the transmission of the disease. The COVID-19 pandemic limited the movement of people and access to quality healthcare. A movement in the healthcare system's focus impacted all healthcare programs worldwide. All resources were diverted to the COVID-19 pandemic, causing existing activities for communicable and non-communicable illnesses to be disrupted. As a result, services such as promotion, pr prevention, treatment, and cure were impacted globally. HIV/AIDS was no exception, and it suffered s a result of the pandemic's effects. According to a modeling exercise undertaken by the WHO and UNAIDS for Sub-Saharan Africa, a disruption in ART supply and preventive programs might increase HIV-related fatalities and new infections across the area. Countries were requested to develop their st strategy to maintain HIV prevention and treatment services during the COVID-19 pandemic as a preventive step. The nations' advances would be wiped unless prompt action was taken to ensure a continuing supply of medications and access to preventative services. However, the HIV Diagnostics market resulted in better growth due to national HIV programs supported by Civil society and international development partners.
Market Size Available
2022 to 2028
2023 to 2028
By Product, Test Type, End-User, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
This market research report on the global HIV diagnostics market has been segmented and sub-segmented based on the product type, test type, end-user, and region.
HIV Diagnostics Market - By Product:
Based on the product, the consumables segment is estimated to play a dominating role among all in the global HIV diagnostics market during the forecast period. Factors such as the increasing incidence of HIV and AIDS, the increased number of hospitals and laboratories, and governments of various countries that have started working aggressively to control HIV/AIDS are expected to favor the segment's growth.
HIV Diagnostics Market - By Test Type:
Qualitative PCR Tests
Based on type, the antibody tests segment is expected to be the leader in the global HIV diagnostics market during the forecast period due to the increasing account of blood donations, rising awareness of HIV and Aids among people, the emergence of novel and innovative medical practices, and technological advancements.
Elisa's test is the next segment that drives the market forward. The enzyme-linked immunosorbent assay (ELISA) tests need patient blood to know antibodies. This test also takes oral fluids and urine to identify positive or negative HIV symptoms.
HIV Diagnostics Market - By End-User:
Based on end-user, the diagnostic laboratories segment is the most lucrative in the global HIV Diagnostics market due to spreading awareness about HIV and AIDS among people in developing countries. Further, the increasing focus of private and government organizations inclines investments in developing advanced diagnostic laboratories with technologically advanced equipment and diagnostic techniques.
HIV Diagnostics Market - By Region:
The global HIV diagnostics market was dominated by North America and accounted for a market share of 38% in the global market in 2020. Y-O-Y growth in the incidence of HIV growing focus of key market participants on developing novel drugs is some of the significant factors propelling the North American market growth. In addition, increasing awareness among people, government initiatives to prevent HIV, widening research, and developing health facilities are further boosting the growth rate of the North American market. In the U.S., the only home test approved by the U.S. Food and Drug Administration is called the Home Access Express Test. Based on this, these people need a further diagnosis, which drives the market forward. In the U.S., HIV tests are free in some areas and available at less cost. Per the Centres for Disease Control and Prevention (CDC), in 2019, nearly34,900 new HIV infections occurred in the United States 2019. HIV screening is most used in Canada, detecting HIV antibodies and the HIV p24 antigen. Rapid HIV test kits have recently been approved for licenses in Canada for point-of-care (POC) testing or self-testing. This requires a few drops of blood from a finger prick and provides results within several minutes. HIV diagnosis and testing is the significant step to knowing the status of the patient's condition. Canada increases testing rates and tests available for people to know about HIV status. Several policies and programs have been conducted across Canada for the prevention and further transmission of HIV.
The Asia Pacific is the next big global and regional market and is growing significantly due to high unmet demand in India and China. In the APAC market, India and China are contributing heavily to the growth of this regional market. China has been in an advanced position in the prevention of HIV for the last three years. The Joint United Nations Programme on HIV/AIDS shows that the number of people suffering has reduced yearly in China. China also launched the prevention of mother-to-child transmission of HIV by undergoing tests and diagnosis, which drives the market forward. Based on diagnosis and treatment, most of the medicine is given to patients who have HIV. India is in the third position in the increasing number of HIV/AIDS cases. According to India's National AIDS Control Program, rapid tests are adopted for the diagnosis of HIV.
The European market is predicted to showcase a promising CAGR between 2020 to 2025. Increase in disposable income and recently developed healthcare equipment to propel the demand of the market. Due to the increasing number of people living with undiagnosed HIV in the European Region, the market has driven the highest market share. In addition, in recent years, diagnoses of HIV have been increasing in this region.
The Middle East and Africa region have slow growth due to a lack of knowledge. In this region, South Africa has the highest HIV prevalence. In 2019, 16.5 million people had HIV (PLHIV) in Africa. Life-saving antiretroviral drugs (ARVs) are manufactured in this region to save lives. HIV infection is the main reason for most of the death in South Africa (S.A.), with the highest mortality rate. Early identification of these HIV symptoms helps with the treatment. Early diagnosis helps in reducing the risk of infection. HIV programs are increased in South Africa to promote awareness of HIV among people and explain how it was acquired. In 2021, sub-Saharan Africa showed a considerable improvement in awareness of HIV. 84% of people are aware of these HIV in sub-Saharan Africa. Free HIV testing was conducted on International AIDS Day in Egypt by Egypt's health ministry. The Egyptian government provides all health services for all patients, especially those with chronic diseases, including AIDS.
KEY MARKET PARTICIPANTS:
Notable participants in this report in the global HIV diagnostics market are Abbott Healthcare, Alere Inc, Bristol-Myers Squibb, Abbvie Inc, Gilead Sciences, Janssen Therapeutics, Merck & Co., Inc, B.D. Biosciences, VIIV Healthcare, Beckman Coulter, Partec, Sysmex, Apogee Flow Systems, Zyomyx Inc., and Mylan Inc.
RECENT MARKET HAPPENINGS:
In 2022, To control HIV transmission AMREF Health Africa launched Afya Kamilifu Project. This Project will reduce the county's high burden of HIV and AIDS. The Project will also launch an HIV data monitoring system using innovative technology to give accurate results to the patients.
In 2020, Atomo signed an agreement with PrEP Health Pty Limited to supply the Atomo HIV Self-Test to PrEP users in Australia.
In 2020, OraSure Technologies developed rapid HIV tests.
In November 2019, the Abbott laboratories' scientist team discovered a new subtype of HIV called HIV-1 Group M, subtype L. The Abbott laboratories team announced the event of this new strain discovery.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]